

Philippe Gaulard

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4427803/publications.pdf>

Version: 2024-02-01

213
papers

22,944
citations

9786

73
h-index

8396

147
g-index

224
all docs

224
docs citations

224
times ranked

14343
citing authors

#	ARTICLE	IF	CITATIONS
1	CHOP Chemotherapy plus Rituximab Compared with CHOP Alone in Elderly Patients with Diffuse Large-B-Cell Lymphoma. <i>New England Journal of Medicine</i> , 2002, 346, 235-242.	27.0	4,928
2	Molecular Diagnosis of Primary Mediastinal B Cell Lymphoma Identifies a Clinically Favorable Subgroup of Diffuse Large B Cell Lymphoma Related to Hodgkin Lymphoma. <i>Journal of Experimental Medicine</i> , 2003, 198, 851-862.	8.5	1,002
3	The gene expression profile of nodal peripheral T-cell lymphoma demonstrates a molecular link between angioimmunoblastic T-cell lymphoma (AITL) and follicular helper T (TFH) cells. <i>Blood</i> , 2007, 109, 4952-4963.	1.4	533
4	Rituximab plus CHOP (R-CHOP) overcomes bcl-2--associated resistance to chemotherapy in elderly patients with diffuse large B-cell lymphoma (DLBCL). <i>Blood</i> , 2003, 101, 4279-4284.	1.4	483
5	[18F]fluoro-2-deoxy-D-glucose positron emission tomography (FDG-PET) in aggressive lymphoma: an early prognostic tool for predicting patient outcome. <i>Blood</i> , 2005, 106, 1376-1381.	1.4	482
6	Hepatosplenic T-cell lymphoma is a rare clinicopathologic entity with poor outcome: report on a series of 21 patients. <i>Blood</i> , 2003, 102, 4261-4269.	1.4	440
7	IDH2 mutations are frequent in angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2012, 119, 1901-1903.	1.4	435
8	Gene expression signatures delineate biological and prognostic subgroups in peripheral T-cell lymphoma. <i>Blood</i> , 2014, 123, 2915-2923.	1.4	435
9	Attenuated immunochemotherapy regimen (R-miniCHOP) in elderly patients older than 80 years with diffuse large B-cell lymphoma: a multicentre, single-arm, phase 2 trial. <i>Lancet Oncology</i> , The, 2011, 12, 460-468.	10.7	420
10	Recurrent TET2 mutations in peripheral T-cell lymphomas correlate with TFH-like features and adverse clinical parameters. <i>Blood</i> , 2012, 120, 1466-1469.	1.4	402
11	Survival Benefit of High-Dose Therapy in Poor-Risk Aggressive Non-Hodgkin's Lymphoma: Final Analysis of the Prospective LNH87-2 Protocol A Groupe d'Etude des Lymphomes de l'Adulte Study. <i>Journal of Clinical Oncology</i> , 2000, 18, 3025-3030.	1.6	400
12	Efficacy of L-asparaginase with methotrexate and dexamethasone (AspaMetDex regimen) in patients with refractory or relapsing extranodal NK/T-cell lymphoma, a phase 2 study. <i>Blood</i> , 2011, 117, 1834-1839.	1.4	346
13	Activating mutations of STAT5B and STAT3 in lymphomas derived from T or NK cells. <i>Nature Communications</i> , 2015, 6, 6025.	12.8	334
14	Mediastinal Gray Zone Lymphoma. <i>American Journal of Surgical Pathology</i> , 2005, 29, 1411-1421.	3.7	305
15	A neuronal receptor, neuropilin-1, is essential for the initiation of the primary immune response. <i>Nature Immunology</i> , 2002, 3, 477-482.	14.5	294
16	Clinical, biologic, and pathologic features in 157 patients with angioimmunoblastic T-cell lymphoma treated within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2008, 111, 4463-4470.	1.4	292
17	Gene expression profiling identifies emerging oncogenic pathways operating in extranodal NK/T-cell lymphoma, nasal type. <i>Blood</i> , 2010, 115, 1226-1237.	1.4	285
18	Immunohistochemical Prognostic Markers in Diffuse Large B-Cell Lymphoma: Validation of Tissue Microarray As a Prerequisite for Broad Clinical Applications A Study From the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2007, 25, 805-812.	1.6	271

#	ARTICLE	IF	CITATIONS
19	Activating mutations in genes related to TCR signaling in angioimmunoblastic and other follicular helper T-cell–derived lymphomas. <i>Blood</i> , 2016, 128, 1490-1502.	1.4	255
20	The Germinal Center/Activated B-Cell Subclassification Has a Prognostic Impact for Response to Salvage Therapy in Relapsed/Refractory Diffuse Large B-Cell Lymphoma: A Bio-CORAL Study. <i>Journal of Clinical Oncology</i> , 2011, 29, 4079-4087.	1.6	248
21	Advances in the understanding and management of angioimmunoblastic T-cell lymphoma. <i>British Journal of Haematology</i> , 2010, 148, 673-689.	2.5	218
22	Expression of CXCL13 by Neoplastic Cells in Angioimmunoblastic T-Cell Lymphoma (AITL). <i>American Journal of Surgical Pathology</i> , 2006, 30, 490-494.	3.7	213
23	MYC-IG rearrangements are negative predictors of survival in DLBCL patients treated with immunochemotherapy: a GELA/LYSA study. <i>Blood</i> , 2015, 126, 2466-2474.	1.4	212
24	Histologic Evolution of Angioimmunoblastic T-cell Lymphoma in Consecutive Biopsies: Clinical Correlation and Insights Into Natural History and Disease Progression. <i>American Journal of Surgical Pathology</i> , 2007, 31, 1077-1088.	3.7	192
25	Peripheral T-cell Lymphomas With a Follicular Growth Pattern are Derived From Follicular Helper T Cells (TFH) and may Show Overlapping Features With Angioimmunoblastic T-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2009, 33, 682-690.	3.7	189
26	Genetic drivers of oncogenic pathways in molecular subgroups of peripheral T-cell lymphoma. <i>Blood</i> , 2019, 133, 1664-1676.	1.4	184
27	Constitutive STAT6 activation in primary mediastinal large B-cell lymphoma. <i>Blood</i> , 2004, 104, 543-549.	1.4	183
28	Gene-expression profiling of systemic anaplastic large-cell lymphoma reveals differences based on ALK status and two distinct morphologic ALK+ subtypes. <i>Blood</i> , 2007, 109, 2156-2164.	1.4	182
29	Recurrent somatic mutations of PTPN1 in primary mediastinal B cell lymphoma and Hodgkin lymphoma. <i>Nature Genetics</i> , 2014, 46, 329-335.	21.4	180
30	Prognostic significance of immunohistochemical biomarkers in diffuse large B-cell lymphoma: a study from the Lunenburg Lymphoma Biomarker Consortium. <i>Blood</i> , 2011, 117, 7070-7078.	1.4	168
31	Integrative clinicopathological and molecular analyses of angioimmunoblastic T-cell lymphoma and other nodal lymphomas of follicular helper T-cell origin. <i>Haematologica</i> , 2017, 102, e148-e151.	3.5	163
32	The Genetic Basis of Hepatosplenic T-cell Lymphoma. <i>Cancer Discovery</i> , 2017, 7, 369-379.	9.4	163
33	Long-Term Outcome of Adults With Systemic Anaplastic Large-Cell Lymphoma Treated Within the Groupe d'Étude des Lymphomes de l'Adulte Trials. <i>Journal of Clinical Oncology</i> , 2012, 30, 3939-3946.	1.6	162
34	Prognostic Significance of MYC Rearrangement and Translocation Partner in Diffuse Large B-Cell Lymphoma: A Study by the Lunenburg Lymphoma Biomarker Consortium. <i>Journal of Clinical Oncology</i> , 2019, 37, 3359-3368.	1.6	161
35	Primary Anaplastic Large-Cell Lymphoma in Adults: Clinical Presentation, Immunophenotype, and Outcome. <i>Blood</i> , 1997, 90, 3727-3734.	1.4	160
36	Indolent T-cell lymphoproliferative disease of the gastrointestinal tract. <i>Blood</i> , 2013, 122, 3599-3606.	1.4	156

#	ARTICLE	IF	CITATIONS
37	Impact of Expert Pathologic Review of Lymphoma Diagnosis: Study of Patients From the French Lymphopath Network. <i>Journal of Clinical Oncology</i> , 2017, 35, 2008-2017.	1.6	155
38	Lenalidomide Maintenance Compared With Placebo in Responding Elderly Patients With Diffuse Large B-Cell Lymphoma Treated With First-Line Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone. <i>Journal of Clinical Oncology</i> , 2017, 35, 2473-2481.	1.6	148
39	Type II enteropathy-associated T-cell lymphoma features a unique genomic profile with highly recurrent SETD2 alterations. <i>Nature Communications</i> , 2016, 7, 12602.	12.8	146
40	MYC + diffuse large B-cell lymphoma is not salvaged by classical R-ICE or R-DHAP followed by BEAM plus autologous stem cell transplantation. <i>Blood</i> , 2012, 119, 4619-4624.	1.4	145
41	Peripheral Tâ€cell and <scp>NK</scp>â€cell lymphomas and their mimics; taking a step forward â€ report on the lymphoma workshop of the <scp>XVI</scp>th meeting of the European Association for Haematopathology and the Society for Hematopathology. <i>Histopathology</i> , 2014, 64, 171-199.	2.9	144
42	Second cancers and late toxicities after treatment of aggressive non-Hodgkin lymphoma with the ACVBP regimen: a GELA cohort study on 2837 patients. <i>Blood</i> , 2003, 103, 1222-1228.	1.4	140
43	MAL Expression in Lymphoid Cells: Further Evidence for MAL as a Distinct Molecular Marker of Primary Mediastinal Large B-Cell Lymphomas. <i>Modern Pathology</i> , 2002, 15, 1172-1180.	5.5	138
44	Primary lymphoma of the liver: Clinical-pathological features and relationship with HCV infection in French patients. <i>Hepatology</i> , 2003, 37, 781-787.	7.3	133
45	Rituximab plus gemcitabine and oxaliplatin in patients with refractory/relapsed diffuse large B-cell lymphoma who are not candidates for high-dose therapy. A phase II Lymphoma Study Association trial. <i>Haematologica</i> , 2013, 98, 1726-1731.	3.5	131
46	Small lymphocytic lymphoma, marginal zone B-cell lymphoma, and mantle cell lymphoma exhibit distinct gene-expression profiles allowing molecular diagnosis. <i>Blood</i> , 2004, 103, 2727-2737.	1.4	127
47	Treatment with 5-azacytidine induces a sustained response in patients with angioimmunoblastic T-cell lymphoma. <i>Blood</i> , 2018, 132, 2305-2309.	1.4	124
48	Nonhepatosplenic Î³Î³ T-cell Lymphomas Represent a Spectrum of Aggressive Cytotoxic T-cell Lymphomas With a Mainly Extranodal Presentation. <i>American Journal of Surgical Pathology</i> , 2011, 35, 1214-1225.	3.7	120
49	Reproducing the molecular subclassification of peripheral T-cell lymphomaâ€NOS by immunohistochemistry. <i>Blood</i> , 2019, 134, 2159-2170.	1.4	120
50	High total metabolic tumor volume at baseline predicts survival independent of response to therapy. <i>Blood</i> , 2020, 135, 1396-1405.	1.4	119
51	Immunoâ€Fluorescence In Situ Hybridization Index Predicts Survival in Patients With Diffuse Large B-Cell Lymphoma Treated With R-CHOP: A GELA Study. <i>Journal of Clinical Oncology</i> , 2009, 27, 5573-5579.	1.6	113
52	Recurrent mutations of the STAT6 DNA binding domain in primary mediastinal B-cell lymphoma. <i>Blood</i> , 2009, 114, 1236-1242.	1.4	111
53	Survival and Clonal Expansion of Mutating â€Forbiddenâ€(Immunoglobulin Receptorâ€Deficient) Epstein-Barr Virusâ€Infected B Cells in Angioimmunoblastic T Cell Lymphoma. <i>Journal of Experimental Medicine</i> , 2001, 194, 927-940.	8.5	106
54	Erythroblasts are a source of angiogenic factors. <i>Blood</i> , 2001, 97, 1968-1974.	1.4	99

#	ARTICLE	IF	CITATIONS
55	The inducible T-cell co-stimulator molecule is expressed on subsets of T cells and is a new marker of lymphomas of T follicular helper cell-derivation. <i>Haematologica</i> , 2010, 95, 432-439.	3.5	99
56	Molecular features of hepatosplenic T-cell lymphoma unravels potential novel therapeutic targets. <i>Blood</i> , 2012, 119, 5795-5806.	1.4	99
57	Angioimmunoblastic T-cell lymphoma is the most common T-cell lymphoma in two distinct French information data sets. <i>Haematologica</i> , 2015, 100, e361-e364.	3.5	98
58	Frequent structural variations involving programmed death ligands in Epstein-Barr virus-associated lymphomas. <i>Leukemia</i> , 2019, 33, 1687-1699.	7.2	98
59	Fluorescence in situ hybridization study of chromosome 7 aberrations in hepatosplenic T-cell lymphoma: Isochromosome 7q as a common abnormality accumulating in forms with features of cytologic progression. <i>Genes Chromosomes and Cancer</i> , 2002, 33, 243-251.	2.8	97
60	The IDH2 R172K mutation associated with angioimmunoblastic T-cell lymphoma produces 2HG in T cells and impacts lymphoid development. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2016, 113, 15084-15089.	7.1	96
61	Detection of t(11;18)(q21;q21) by interphase fluorescence in situ hybridization using API2 and MLT-specific probes. <i>Blood</i> , 2000, 96, 2215-2218.	1.4	95
62	VJ REARRANGEMENTS OF THE TCR β LOCUS IN PERIPHERAL T-CELL LYMPHOMAS: ANALYSIS BY POLYMERASE CHAIN REACTION AND DENATURING GRADIENT GEL ELECTROPHORESIS. , 1996, 178, 303-310.		93
63	Hepatosplenic $\hat{I}\hat{I}^2$ T-Cell Lymphoma. <i>American Journal of Surgical Pathology</i> , 2000, 24, 1027-1032.	3.7	90
64	Romidepsin Plus CHOP Versus CHOP in Patients With Previously Untreated Peripheral T-Cell Lymphoma: Results of the Ro-CHOP Phase III Study (Conducted by LYSA). <i>Journal of Clinical Oncology</i> , 2022, 40, 242-251.	1.6	90
65	Immunohistochemistry as a valuable tool to assess CD30 expression in peripheral T-cell lymphomas: high correlation with mRNA levels. <i>Blood</i> , 2014, 124, 2983-2986.	1.4	89
66	Cytotoxic protein expression in natural killer cell lymphomas and in $\hat{I}\hat{I}^2$ and $\hat{I}\hat{I}^3$ peripheral T-cell lymphomas. <i>Journal of Pathology</i> , 1997, 183, 432-439.	4.5	87
67	Primary breast non-Hodgkin's lymphoma: A large single center study of initial characteristics, natural history, and prognostic factors. <i>American Journal of Hematology</i> , 2009, 84, 133-139.	4.1	87
68	Follicular helper T cells: implications in neoplastic hematopathology. <i>Seminars in Diagnostic Pathology</i> , 2011, 28, 202-213.	1.5	86
69	Cytotoxic T-cell and NK-cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2014, 38, e60-e71.	3.7	83
70	Gene alterations in epigenetic modifiers and JAK-STAT signaling are frequent in breast implant-associated ALCL. <i>Blood</i> , 2020, 135, 360-370.	1.4	80
71	Follicular Peripheral T-cell Lymphoma Expands the Spectrum of Classical Hodgkin Lymphoma Mimics. <i>American Journal of Surgical Pathology</i> , 2012, 36, 1636-1646.	3.7	79
72	Young Patients With Non-Germinal Center B-Cell-Like Diffuse Large B-Cell Lymphoma Benefit From Intensified Chemotherapy With ACVBP Plus Rituximab Compared With CHOP Plus Rituximab: Analysis of Data From the Groupe d'Etudes des Lymphomes de l'Adulte/Lymphoma Study Association Phase III Trial LNH 03-2B. <i>Journal of Clinical Oncology</i> , 2014, 32, 3996-4003.	1.6	79

#	ARTICLE	IF	CITATIONS
73	Recurrent mutations of the exportin 1 gene (XPO1) and their impact on selective inhibitor of nuclear export compounds sensitivity in primary mediastinal B-cell lymphoma. <i>American Journal of Hematology</i> , 2016, 91, 923-930.	4.1	79
74	Peripheral T-cell lymphoma presenting as predominant liver disease: A report of three cases. <i>Hepatology</i> , 1986, 6, 864-868.	7.3	78
75	Global Promoter Methylation Analysis Reveals Novel Candidate Tumor Suppressor Genes in Natural Killer Cell Lymphoma. <i>Clinical Cancer Research</i> , 2015, 21, 1699-1711.	7.0	78
76	Targeting intratumoral B cells with rituximab in addition to CHOP in angioimmunoblastic T-cell lymphoma. A clinicobiological study of the GELA. <i>Haematologica</i> , 2012, 97, 1594-1602.	3.5	76
77	Human Interleukin-10 Expression in T/Natural Killer-Cell Lymphomas. <i>American Journal of Pathology</i> , 1998, 153, 1229-1237.	3.8	75
78	Bone Marrow Involvement in Lymphomas With Hemophagocytic Syndrome at Presentation. <i>American Journal of Surgical Pathology</i> , 2001, 25, 865-874.	3.7	73
79	The mutator pathway is a feature of immunodeficiency-related lymphomas. <i>Proceedings of the National Academy of Sciences of the United States of America</i> , 2004, 101, 5002-5007.	7.1	68
80	Small nucleolar RNA expression profiling identifies potential prognostic markers in peripheral T-cell lymphoma. <i>Blood</i> , 2012, 120, 3997-4005.	1.4	68
81	Molecular classification of T-cell lymphomas. <i>Critical Reviews in Oncology/Hematology</i> , 2009, 72, 125-143.	4.4	67
82	T-cell lymphomas. <i>Seminars in Hematology</i> , 2003, 40, 233-243.	3.4	66
83	Hodgkin Lymphoma-associated Hemophagocytic Syndrome: A Disorder Strongly Correlated with Epstein-Barr Virus. <i>Clinical Infectious Diseases</i> , 2008, 47, 531-534.	5.8	66
84	Molecular underpinning of extranodal NK/T-cell lymphoma. <i>Best Practice and Research in Clinical Haematology</i> , 2013, 26, 57-74.	1.7	64
85	Expression of the granzyme B inhibitor PI9 predicts outcome in nasal NK/T-cell lymphoma: results of a Western series of 48 patients treated with first-line polychemotherapy within the Groupe d'Etude des Lymphomes de l'Adulte (GELA) trials. <i>Blood</i> , 2007, 109, 2183-2189.	1.4	63
86	Bone marrow histologic and immunohistochemical findings in peripheral T-cell lymphoma: A study of 38 cases. <i>Human Pathology</i> , 1991, 22, 331-338.	2.0	62
87	CD10 delineates a subset of human IL-4 producing follicular helper T cells involved in the survival of follicular lymphoma B cells. <i>Blood</i> , 2015, 125, 2381-2385.	1.4	61
88	Best Practices Guideline for the Pathologic Diagnosis of Breast Implant-associated Anaplastic Large-Cell Lymphoma. <i>Journal of Clinical Oncology</i> , 2020, 38, 1102-1111.	1.6	61
89	Characterization of CXCL13+ Neoplastic T Cells in Cutaneous Lesions of Angioimmunoblastic T-cell Lymphoma (AITL). <i>American Journal of Surgical Pathology</i> , 2007, 31, 1068-1076.	3.7	58
90	CD30-positive peripheral T-cell lymphomas share molecular and phenotypic features. <i>Haematologica</i> , 2013, 98, 1250-1258.	3.5	56

#	ARTICLE	IF	CITATIONS
91	The pathological features of angioimmunoblastic T-cell lymphomas with IDH2 mutations. <i>Modern Pathology</i> , 2019, 32, 1123-1134.	5.5	54
92	HACE1 Is a Tumor Suppressor Gene Candidate in Natural Killer Cell Neoplasms. <i>American Journal of Pathology</i> , 2013, 182, 49-55.	3.8	52
93	The reliability of immunohistochemical analysis of the tumor microenvironment in follicular lymphoma: a validation study from the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2014, 99, 715-725.	3.5	52
94	Alemtuzumab plus CHOP versus CHOP in elderly patients with peripheral T-cell lymphoma: the DSHNHL2006-1B/ACT-2 trial. <i>Leukemia</i> , 2021, 35, 143-155.	7.2	52
95	Blastic plasmacytoid dendritic cell neoplasm: the first report of two cases treated by 5-azacytidine. <i>European Journal of Haematology</i> , 2014, 93, 81-85.	2.2	51
96	Pathology and biology of peripheral T-cell lymphomas. <i>Histopathology</i> , 2011, 58, 49-68.	2.9	50
97	Pathology of Peripheral T-Cell Lymphomas: Where Do We Stand?. <i>Seminars in Hematology</i> , 2014, 51, 5-16.	3.4	48
98	The microenvironment in T-cell lymphomas: Emerging themes. <i>Seminars in Cancer Biology</i> , 2014, 24, 49-60.	9.6	48
99	Efficacy of 5-azacytidine in a TET2 mutated angioimmunoblastic T cell lymphoma. <i>British Journal of Haematology</i> , 2015, 168, 913-916.	2.5	48
100	Intraepidermal localization of the clone in cutaneous T-cell lymphoma. <i>Journal of the American Academy of Dermatology</i> , 1992, 27, 589-593.	1.2	47
101	Association of Primary Pleural Effusion Lymphoma of T-Cell Origin and Human Herpesvirus 8 in a Human Immunodeficiency Virus-Seronegative Man. <i>Archives of Pathology and Laboratory Medicine</i> , 2001, 125, 1246-1248.	2.5	47
102	Clinical impact of recurrently mutated genes on lymphoma diagnostics: state-of-the-art and beyond. <i>Haematologica</i> , 2016, 101, 1002-1009.	3.5	43
103	Primary lymphoma of the liver. <i>Liver</i> , 1993, 13, 57-61.	0.1	40
104	Heterozygosity for Roquinsan leads to angioimmunoblastic T-cell lymphoma-like tumors in mice. <i>Blood</i> , 2012, 120, 812-821.	1.4	40
105	Prognostic relevance of CD163 and CD8 combined with EZH2 and gain of chromosome 18 in follicular lymphoma: a study by the Lunenburg Lymphoma Biomarker Consortium. <i>Haematologica</i> , 2017, 102, 1413-1423.	3.5	39
106	Somatic IL4R mutations in primary mediastinal large B-cell lymphoma lead to constitutive JAK-STAT signaling activation. <i>Blood</i> , 2018, 131, 2036-2046.	1.4	39
107	Integrative analysis of a phase 2 trial combining lenalidomide with CHOP in angioimmunoblastic T-cell lymphoma. <i>Blood Advances</i> , 2021, 5, 539-548.	5.2	38
108	Pathologic and Clinical Features of 77 Hodgkin's Lymphoma Patients Treated in a Lymphoma Protocol (LNH87). <i>American Journal of Surgical Pathology</i> , 2001, 25, 297-306.	3.7	37

#	ARTICLE	IF	CITATIONS
109	Mediastinal Lymphoma: Quantitative Changes in Gadolinium Enhancement at MR Imaging after Treatment. <i>Radiology</i> , 2001, 219, 621-628.	7.3	36
110	Peripheral T-cell lymphomas of follicular helper T-cell type frequently display an aberrant CD3 ^{hi} /dimCD4 ⁺ population by flow cytometry: an important clue to the diagnosis of a Hodgkin lymphoma mimic. <i>Modern Pathology</i> , 2016, 29, 1173-1182.	5.5	36
111	Expression of p53 protein in T- and natural killer-cell lymphomas is associated with some clinicopathologic entities but rarely related to p53 mutations. <i>Human Pathology</i> , 2001, 32, 196-204.	2.0	34
112	GAPDH Overexpression in the T Cell Lineage Promotes Angioimmunoblastic T Cell Lymphoma through an NF- κ B-Dependent Mechanism. <i>Cancer Cell</i> , 2019, 36, 268-287.e10.	16.8	34
113	CD30+ lymphoproliferative disorders. <i>Haematologica</i> , 2010, 95, 1627-1630.	3.5	33
114	Early lesions in lymphoid neoplasia. <i>Journal of Hematopathology</i> , 2012, 5, 169-199.	0.4	33
115	CD10 expression in diffuse large B-cell lymphomas does not influence survival. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2004, 445, 545-551.	2.8	32
116	New insights into breast implant-associated anaplastic large cell lymphoma. <i>Current Opinion in Oncology</i> , 2018, 30, 292-300.	2.4	31
117	New insights in the pathogenesis of T-cell lymphomas. <i>Current Opinion in Oncology</i> , 2018, 30, 277-284.	2.4	31
118	Brentuximab vedotin in refractory or relapsed peripheral T-cell lymphomas: the French named patient program experience in 56 patients. <i>Haematologica</i> , 2016, 101, e103-e106.	3.5	30
119	Treatment with Hypomethylating Agent 5-Azacytidine Induces Sustained Response in Angioimmunoblastic T Cell Lymphomas. <i>Blood</i> , 2016, 128, 4164-4164.	1.4	30
120	Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 272-279.	2.5	29
121	Increased expression of interleukin-4 during liver allograft rejection. <i>Journal of Hepatology</i> , 1999, 30, 935-943.	3.7	28
122	RNA fusions involving <i>CD28</i> are rare in peripheral T-cell lymphomas and concentrate mainly in those derived from follicular helper T cells. <i>Haematologica</i> , 2018, 103, e360-e363.	3.5	27
123	Regulatory T-Cell Depletion in Angioimmunoblastic T-Cell Lymphoma. <i>American Journal of Pathology</i> , 2010, 177, 570-574.	3.8	26
124	The Need for a Consensus Next-Generation Sequencing Panel for Mature Lymphoid Malignancies. <i>HemaSphere</i> , 2019, 3, e169.	2.7	26
125	Defining signatures of peripheral T-cell lymphoma with a targeted 20-marker gene expression profiling assay. <i>Haematologica</i> , 2020, 105, 1582-1592.	3.5	26
126	In angioimmunoblastic T-cell lymphoma, neoplastic T cells may be a minor cell population. A molecular single-cell and immunohistochemical study. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2005, 446, 15-20.	2.8	25

#	ARTICLE	IF	CITATIONS
127	Cellular origin of T-cell lymphomas. <i>Blood</i> , 2014, 123, 2909-2910.	1.4	25
128	Respective prognostic values of germinal center phenotype and early 18fluorodeoxyglucose-positron emission tomography scanning in previously untreated patients with diffuse large B-cell lymphoma. <i>Haematologica</i> , 2007, 92, 778-783.	3.5	24
129	câ€Maf expression in angioimmunoblastic Tâ€cell lymphoma reflects follicular helper Tâ€cell derivation rather than oncogenesis. <i>Histopathology</i> , 2012, 60, 371-376.	2.9	24
130	Clinical spectrum, evolution, and management of autoimmune cytopenias associated with angioimmunoblastic Tâ€cell lymphoma. <i>European Journal of Haematology</i> , 2019, 103, 35-42.	2.2	24
131	Loss of 5-hydroxymethylcytosine is a frequent event in peripheral T-cell lymphomas. <i>Haematologica</i> , 2018, 103, e115-e118.	3.5	23
132	Combining gene expression profiling and machine learning to diagnose B-cell non-Hodgkin lymphoma. <i>Blood Cancer Journal</i> , 2020, 10, 59.	6.2	22
133	Expression of TFH Markers and Detection of RHOA p.G17V and IDH2 p.R172K/S Mutations in Cutaneous Localizations of Angioimmunoblastic T-Cell Lymphomas. <i>American Journal of Surgical Pathology</i> , 2017, 41, 1581-1592.	3.7	21
134	Multiple Ways to Detect IDH2 Mutations in Angioimmunoblastic T-Cell Lymphoma from Immunohistochemistry to Next-Generation Sequencing. <i>Journal of Molecular Diagnostics</i> , 2018, 20, 677-685.	2.8	21
135	Super-enhancer-based identification of a BATF3/IL-2Râ€ module reveals vulnerabilities in anaplastic large cell lymphoma. <i>Nature Communications</i> , 2021, 12, 5577.	12.8	21
136	Detection of Gene Fusion Transcripts in Peripheral T-Cell Lymphoma Using a Multiplexed Targeted Sequencing Assay. <i>Journal of Molecular Diagnostics</i> , 2021, 23, 929-940.	2.8	20
137	Adult T cell leukemia aggressiveness correlates with loss of both 5-hydroxymethylcytosine and TET2 expression. <i>Oncotarget</i> , 2017, 8, 52256-52268.	1.8	20
138	Extranodal NK/T-Cell Lymphoma: Toward the Identification of Clinical Molecular Targets. <i>Journal of Biomedicine and Biotechnology</i> , 2011, 2011, 1-11.	3.0	19
139	New biomarkers in T-cell lymphomas. <i>Best Practice and Research in Clinical Haematology</i> , 2012, 25, 13-28.	1.7	19
140	CD1d-restricted peripheral T cell lymphoma in mice and humans. <i>Journal of Experimental Medicine</i> , 2016, 213, 841-857.	8.5	19
141	Long-term outcomes of adults with first-relapsed/refractory systemic anaplastic large-cell lymphoma in theâ€pre-brentuximab vedotin era: A LYSA/SFGM-TC study. <i>European Journal of Cancer</i> , 2017, 83, 146-153.	2.8	18
142	ICOS is widely expressed in cutaneous T-cell lymphoma, and its targeting promotes potent killing of malignant cells. <i>Blood Advances</i> , 2020, 4, 5203-5214.	5.2	18
143	The mechanisms underlying MMR deficiency in immunodeficiencyâ€related nonâ€Hodgkin lymphomas are different from those in other sporadic microsatellite instable neoplasms. <i>International Journal of Cancer</i> , 2009, 125, 2360-2366.	5.1	17
144	Rituximab plus gemcitabine and oxaliplatin (R-GemOx) in refractory/relapsed diffuse large B-cell lymphoma: a real-life study in patients ineligible for autologous stem-cell transplantation. <i>Leukemia and Lymphoma</i> , 2021, 62, 2161-2168.	1.3	17

#	ARTICLE	IF	CITATIONS
145	Hepatosplenic T cell lymphoma responsive to 2-â€²-deoxycoformycin therapy. American Journal of Hematology, 2010, 85, 727-729.	4.1	16
146	Ten-Year Relative Survival and Causes of Death in Elderly Patients Treated With R-CHOP or CHOP in the GELA LNH-985 Trial. Clinical Lymphoma, Myeloma and Leukemia, 2012, 12, 151-154.	0.4	16
147	Diagnostic and Biological Significance of KIR Expression Profile Determined by RNA-Seq in Natural Killer/T-Cell Lymphoma. American Journal of Pathology, 2016, 186, 1435-1441.	3.8	16
148	<i>Idh1</i> mutations contribute to the development of T-cell malignancies in genetically engineered mice. Proceedings of the National Academy of Sciences of the United States of America, 2016, 113, 1387-1392.	7.1	16
149	Reliable subtype classification of diffuse large B-cell lymphoma samples from GELA LNH2003 trials using the Lymph2Cx gene expression assay. Haematologica, 2017, 102, e404-e406.	3.5	16
150	Nodal cytotoxic peripheral T-cell lymphoma occurs frequently in the clinical setting of immunodysregulation and is associated with recurrent epigenetic alterations. Modern Pathology, 2022, 35, 1126-1136.	5.5	16
151	Nodal follicular helper T-cell lymphoma may present with different patterns. A case report. Human Pathology, 2009, 40, 264-269.	2.0	15
152	ROQUIN/RC3H1 Alterations Are Not Found in Angioimmunoblastic T-Cell Lymphoma. PLoS ONE, 2013, 8, e64536.	2.5	15
153	Lenalidomide maintenance for diffuse large B-cell lymphoma patients responding to R-â€²CHOP: quality of life, dosing, and safety results from the randomised controlled REMARC study. British Journal of Haematology, 2020, 189, 84-96.	2.5	15
154	Primary Hepatic Lymphoma of Mucosa-Associated Lymphoid Tissue Type: A Case Report With Cytogenetic Study. International Journal of Surgical Pathology, 2008, 16, 301-307.	0.8	14
155	New preclinical models for angioimmunoblastic T-cell lymphoma: filling the GAP. Oncogenesis, 2020, 9, 73.	4.9	14
156	Angioimmunoblastic T-Cell Lymphoma and Chronic Lymphocytic Leukemia/Small Lymphocytic Lymphoma. American Journal of Surgical Pathology, 2021, 45, 773-786.	3.7	14
157	HHV8-related non-Hodgkin's lymphoma of the spermatic cord in a patient with HIV-associated multicentric Castleman disease. American Journal of Hematology, 2003, 72, 70-71.	4.1	13
158	Bendamustine for the treatment of relapsed or refractory peripheral T cell lymphomas: A French retrospective multicenter study. Oncotarget, 2016, 7, 85573-85583.	1.8	13
159	Tricky and Terrible T-Cell Tumors: These are Thrilling Times for Testing: Molecular Pathology of Peripheral T-Cell Lymphomas. Hematology American Society of Hematology Education Program, 2011, 2011, 336-343.	2.5	12
160	Epidermotropic secondary cutaneous involvement by relapsed angioimmunoblastic <sc>T</sc>-cell lymphoma mimicking mycosis fungoides: a case report. Journal of Cutaneous Pathology, 2012, 39, 1119-1124.	1.3	12
161	First Analysis of an International Double-Blind Randomized Phase III Study of Lenalidomide Maintenance in Elderly Patients with DLBCL Treated with R-CHOP in First Line, the Remarc Study from Lysa. Blood, 2016, 128, 471-471.	1.4	12
162	DNA methylation profiling of hepatosplenic T-cell lymphoma. Haematologica, 2019, 104, e104-e107.	3.5	11

#	ARTICLE	IF	CITATIONS
163	A Comprehensive Clinicopathologic and Molecular Study of 19 Primary Effusion Lymphomas in HIV-infected Patients. <i>American Journal of Surgical Pathology</i> , 2022, 46, 353-362.	3.7	11
164	Central nervous system relapse in patients over 80 years with diffuse large B-cell lymphoma: an analysis of two <sc>LYSA</sc> studies. <i>Cancer Medicine</i> , 2018, 7, 539-548.	2.8	10
165	Outcome is not improved by the use of alternating chemotherapy in elderly patients with aggressive lymphoma. <i>The Hematology Journal</i> , 2001, 2, 279-285.	1.4	10
166	Peripheral <sc>T</sc>-cell lymphoma in <sc>HIV</sc>-infected patients: a study of 17 cases in the combination antiretroviral therapy era. <i>British Journal of Haematology</i> , 2013, 161, 843-851.	2.5	9
167	EBV+ diffuse large B-cell lymphoma associated with chronic inflammation expands the spectrum of breast implant-related lymphomas. <i>Blood</i> , 2020, 135, 2004-2009.	1.4	9
168	Overcoming IMiD resistance in T-cell lymphomas through potent degradation of ZFP91 and IKZF1. <i>Blood</i> , 2022, 139, 2024-2037.	1.4	9
169	Pathobiology and Molecular Profiling of Peripheral T-Cell Lymphomas. <i>Hematology American Society of Hematology Education Program</i> , 2008, 2008, 272-279.	2.5	8
170	Novel T Follicular Helper-like T-Cell Lymphoma Therapies: From Preclinical Evaluation to Clinical Reality. <i>Cancers</i> , 2022, 14, 2392.	3.7	7
171	ALK-negative anaplastic large-cell lymphoma. <i>Blood</i> , 2016, 127, 175-177.	1.4	6
172	Follicular variant of peripheral T cell lymphoma with mediastinal involvement in a child: a case report. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2015, 466, 351-355.	2.8	5
173	Controversies in the Treatment of Peripheral T-cell Lymphoma. <i>HemaSphere</i> , 2020, 4, e461.	2.7	5
174	Prolonged Remissions After Nivolumab Plus Gemcitabine/Oxaliplatin in Relapsed/Refractory T-cell Lymphoma. <i>HemaSphere</i> , 2022, 6, e672.	2.7	5
175	Evaluation of a low density DNA microarray for small B-cell non-Hodgkin lymphoma differential diagnosis. <i>Leukemia and Lymphoma</i> , 2009, 50, 410-418.	1.3	4
176	Definition of a minimal genes set for mature lymphoid blood diseases. <i>Hematologie</i> , 2018, 24, 27-59.	0.0	4
177	Chronic T cell receptor stimulation unmasks NK receptor signaling in peripheral T cell lymphomas via epigenetic reprogramming. <i>Journal of Clinical Investigation</i> , 2021, 131, .	8.2	4
178	ICOS Is Widely Expressed in Cutaneous T-Cell Lymphoma and Its Targeting Promotes Potent Killing of Malignant Cells. <i>Blood</i> , 2021, 138, 790-790.	1.4	4
179	New Insights into the Molecular Pathogenesis of T-Cell Lymphomas. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2019, 19, S106-S108.	0.4	3
180	Exclusive B-cell phenotype of primary prostatic lymphomas: a potential role of chronic prostatitis. <i>Histopathology</i> , 2020, 76, 767-773.	2.9	3

#	ARTICLE	IF	CITATIONS
181	Characteristics of T- and NK-cell Lymphomas After Renal Transplantation: A French National Multicentric Cohort Study. <i>Transplantation</i> , 2021, 105, 1858-1868.	1.0	3
182	The Gene Expression Profile of Nodal T-Cell Lymphomas Identifies a Molecular Link between Angioimmunoblastic T-Cell Lymphoma (AITL) and Follicular Helper T Cells (TFH), and between CD30+ Peripheral T-Cell Lymphoma and ALK-Negative Anaplastic Large Cell Lymphoma (ALCL).. <i>Blood</i> , 2006, 108, 289-289.	1.4	3
183	Angioimmunoblastic T-Cell Lymphoma (AITL) Is the Most Prevalent T-Cell Lymphoma Entity in Western Europe. <i>Blood</i> , 2012, 120, 1607-1607.	1.4	3
184	Breast Implant Associated-Anaplastic Large Cell Lymphoma (BIA-ALCL): The French Lymphoma Study Association (LYSA) registry data.. <i>Journal of Clinical Oncology</i> , 2018, 36, 7554-7554.	1.6	3
185	VEGF121, is predictor for survival in activated B-cell-like diffuse large B-cell lymphoma and is related to an immune response gene signature conserved in cancers. <i>Oncotarget</i> , 2017, 8, 90808-90824.	1.8	3
186	Cutaneous presentation of enteropathy-associated T-cell lymphoma masquerading as a DUSP22-rearranged CD30+ lymphoproliferation. <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2022, 481, 653-657.	2.8	3
187	VIII. New markers in peripheral T-cell lymphomas: more entities or more confusion?. <i>Hematological Oncology</i> , 2013, 31, 51-56.	1.7	2
188	Mature T-cell lymphomas. <i>Diagnostic Histopathology</i> , 2015, 21, 408-420.	0.4	2
189	Immunomodulatory antibodies for the treatment of lymphoma: Report on the CALYM Workshop. <i>Oncolmmunology</i> , 2016, 5, e1186323.	4.6	2
190	Effect of expression of ICOS in cutaneous T-cell lymphoma and its targeting on killing of malignant cells.. <i>Journal of Clinical Oncology</i> , 2020, 38, e20040-e20040.	1.6	2
191	Progressive hemispheric atrophy in HIV: A Rasmussen's-like variant of CD8 encephalitis?. <i>Neuropathology and Applied Neurobiology</i> , 2022, 48, .	3.2	2
192	Angioimmunoblastic T-Cell Lymphoma: A Clinicopathologic Study of 158 Patients Treated in GELA (Groupe d'Étude des Lymphomes de l'Adulte) Trials.. <i>Blood</i> , 2006, 108, 397-397.	1.4	1
193	Expert central review in lymphoma diagnosis. Is there a need?. <i>Oncotarget</i> , 2017, 8, 114426-114427.	1.8	1
194	PD1 in Scleroderma syndrome: a repressor of cell survival sometimes lost during progression, but a new target using depleting antibodies?. <i>European Journal of Cancer</i> , 2021, 156, S14-S15.	2.8	1
195	ICOS is widely expressed in cutaneous T-cell lymphoma and its targeting promotes potent killing of malignant cells. <i>European Journal of Cancer</i> , 2021, 156, S23-S24.	2.8	1
196	Misleading Features of Bone Marrow Involvement by Peripheral T-Cell Lymphomas. , 2012, , 253-270.		1
197	The EHA Research Roadmap: Malignant Lymphoid Diseases. <i>HemaSphere</i> , 2022, 6, e726.	2.7	1
198	Virus epstein-barr et lymphomes T/NK : intérêt physiopathologique et pratique. <i>Revue Francaise Des Laboratoires</i> , 2001, 2001, 65-72.	0.0	0

#	ARTICLE	IF	CITATIONS
199	Biology of T-Cell Lymphoma. <i>Clinical Lymphoma, Myeloma and Leukemia</i> , 2018, 18, S95-S96.	0.4	0
200	Complete remission of agranulocytosis after splenectomy in a variant form of T-cell large granular lymphocyte leukemia. <i>Leukemia and Lymphoma</i> , 2019, 60, 254-257.	1.3	0
201	Molecular and Clinical Aspects of Angioimmunoblastic T-Cell Lymphoma. , 2013, , 57-69.		0
202	Number of Circulating t(14;18) Tumor Cells at Diagnosis Is Related to, but Add to the Prognostic Value of Metabolic Tumor Burden in Follicular Lymphoma. <i>Blood</i> , 2015, 126, 3872-3872.	1.4	0
203	Gene Expression Profiling Using a Reverse Transcriptase-Multiplex Ligation Dependant Probe Amplification Assay Allows for an Accurate Classification of Peripheral T-Cell Lymphoma and Highlights Novel Subgroups within the PTCL-NOS Category. <i>Blood</i> , 2016, 128, 2932-2932.	1.4	0
204	Clinical Spectrum, Evolution and Management of Autoimmune Cytopenia Associated with Angioimmunoblastic T-Cell Lymphoma: A Retrospective, Multicenter Study. <i>Blood</i> , 2016, 128, 1816-1816.	1.4	0
205	Incidence and Risk Factors for Central Nervous System Relapse in Very Elderly Patients over 80 with Diffuse Large B-Cell Lymphoma: A Retrospective Analysis of Two Lysa Studies. <i>Blood</i> , 2016, 128, 927-927.	1.4	0
206	Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Encyclopedia of Pathology</i> , 2019, , 1-10.	0.0	0
207	Hepatosplenic T-Cell Lymphoma. <i>Encyclopedia of Pathology</i> , 2019, , 1-9.	0.0	0
208	Hepatosplenic T-Cell Lymphoma. <i>Encyclopedia of Pathology</i> , 2020, , 206-214.	0.0	0
209	Analysis of a Safety Run-in Cohort from Niveau, a Phase 3 Study for Patients with Aggressive Non-Hodgkin Lymphoma in First Relapse or Progression Not Eligible for High-Dose Chemotherapy (HDT), Testing Nivolumab in Combination with Gemcitabine, Oxaliplatin (GemOx) Plus Rituximab (R) in Case of B-Cell Lymphoma. <i>Blood</i> , 2019, 134, 4085-4085.	1.4	0
210	Peripheral T-Cell Lymphoma, Not Otherwise Specified. <i>Encyclopedia of Pathology</i> , 2020, , 395-404.	0.0	0
211	A Molecular Classifier Increased the Accuracy of Lymphoma Diagnosis By Expert Pathologists in the Diffuse Large B-Cell Lymphoma Gained Trial from the Lysa. <i>Blood</i> , 2021, 138, 3495-3495.	1.4	0
212	Nivolumab in Combination with Gemcitabine and Oxaliplatin (GemOx) in Relapse/Refractory T-Cell Lymphoma: Preliminary Results of the Experimental Arm of the Niveau Trial. <i>Blood</i> , 2020, 136, 33-34.	1.4	0
213	Standard chemotherapy followed by allogeneic or autologous transplantation: The role of allogeneic transplantation in the AATT study.. <i>Journal of Clinical Oncology</i> , 2022, 40, 7534-7534.	1.6	0